Translational Relevance 40
Inhibiting the VEGF signaling pathway is important when treating patients with advanced cancer. Despite the benefits shown when combining bevacizumab with cytotoxic chemotherapy in certain solid malignancies, investigations combining VEGFR TKIs with cytotoxic chemotherapy have not shown similar promise despite higher single-agent activity of VEGFR 45 TKIs compared to bevacizumab. This has raised questions whether concurrent VEGFR TKIs may be diminishing the effect of cytotoxic chemotherapy, and whether alternative dosing strategies may be better. Given the number of newer VEGFR TKIs in development, understanding of the pharmacodynamics effects of VEGFR TKIs in patients is needed. Here we present a pharmacodynamics study using FLT PET/CT in patients treated with sunitinib. This 50 study provides new insight into the VEGFR TKI withdrawal flare and how this knowledge may be incorporated into more optimal sequencing strategies with these agents. Additionally, this study highlights the power of using functional imaging to assist in early drug development.
Introduction
In 1971, Judah Folkman hypothesized that angiogenesis plays an integral role in tumor growth.
(1) As a result, inhibiting angiogenesis was considered a reasonable strategy to prevent tumor progression and metastasis. Currently, the vascular endothelial growth factor (VEGF)
signaling pathway is the best-described target for anti-angiogenic treatment. Since 2004, 80 multiple VEGF signaling pathway (VSP) inhibitors have been approved by the US Food and Drug Administration (FDA) based on improvements in overall survival (OS) and/or progressionfree survival (PFS) validating this target. The first of these drugs approved was bevacizumab, a humanized monoclonal antibody against VEGF. While its single-agent activity in most solid malignancies was low, (2, 3) it is approved for use in metastatic colorectal cancer (CRC)(4, 5) 85
and non-small cell lung carcinoma (NSCLC)(6) due to improvements in OS when combined with cytotoxic chemotherapy. In comparison, newer agents that target the VEGF receptor (VEGFR) tyrosine kinase inhibitor (TKI) have resulted in higher single-agent activity compared to bevacizumab. Multiple VEGFR TKIs, including sorafenib, sunitinib, and pazopanib, are now approved as monotherapy in metastatic renal cell carcinoma (mRCC), (7) (8) (9) (10) (11) and gastrointestinal 90 stromal tumors. (12) Despite relatively modest OS improvements, all of these clinical studies confirm that targeting angiogenesis is a validated treatment strategy.
Sunitinib malate is a receptor tyrosine kinase inhibitor (TKI) that exerts its key mechanism of action in mRCC through inhibition of VEGF receptors (VEGFR) -1, -2, and -3 and platelet derived growth factor receptors (PDGFR) -α and -β on tumor vascular 95 endothelium. (13) The approved schedule is 50 mg by mouth daily for 4 weeks followed by a 2 week break (4/2 schedule); however, sunitinib has also been studied on a 2/1 schedule. progression-free survival with sunitinib with an investigator-reported objective response rate (ORR) for sunitinib of 47% (3% complete responses). (10) Reports in the literature of CRs in 100 mRCC patients treated with sunitinib have remained consistently low. (15) (16) (17) In contrast to sunitinib, single-agent bevacizumab appears to produce a relatively modest ORR and PFS of 10 to 13% and 4.8 to 8.5 months, respectively. (18, 19) Overall, all patients eventually progress on anti-angiogenic therapy. This has generated many questions as to how patients become resistant to anti-angiogenic drugs and led many investigators to empirically combine sunitinib with other 105 agents in an attempt to prolong benefit.
We have observed that patients with mRCC treated with sunitinib on the 4/2 schedule can achieve clinical improvement in sites of painful metastases during sunitinib exposure, but can develop recurrent pain within 4 to 5 days of stopping sunitinib. We suspected that this VEGFR TKI withdrawal flare may be associated with a period of rapid, transient tumor re-growth, (20, 110 21) and that the pain would decrease with resumption of therapy. We suggested that during this "flare," the tumor would be more engaged in S-phase of the cell cycle (proliferation) and thus more responsive to cytotoxic chemotherapy. However, several key questions remain: 1) whether the VEGFR TKI withdrawal flare is common; 2) whether it is specific to clear cell renal cell carcinoma, as opposed to other solid tumor types; and 3) whether the flare represents a true 115 increase in tumor cell proliferation (instead of an inflammatory or vascular effect). Based on our clinical observations and available clinical trial and preclinical data, we hypothesized that there is a period of rapid tumor progression in most solid tumors following acute cessation of sunitinib. This study was designed to explore this hypothesis by using molecular imaging to better understand the pharmacodynamic changes with sunitinib. As sunitinib is administered 120 6 of 26 and during acute treatment withdrawal. Better understanding of the pharmacodynamic changes with sunitinib would also provide necessary understanding to test the second hypothesis of synergistic combination of VEGFR TKI with cytotoxic therapy. This study was designed and conducted at the University of Wisconsin Carbone Cancer Center. The goal was to use FLT PET/CT to characterize and quantify changes in tumor proliferation during sunitinib exposure and temporary withdrawal, explore pharmacodynamic changes that may yield insight into predicting treatment response/failure, and gain further insight regarding the physiologic effects of VEGFR TKI in patients with advanced malignancies. In 135 addition to clinical outcomes, the aim was to correlate FLT PET/CT imaging results with both sunitinib pharmacokinetic (PK) and plasma VEGF levels as potential explanations for the withdrawal flare.
Patients and Methods 140

Patient Selection
Patients were required to have histologically or cytologically confirmed renal cell cancer or any other solid malignancy (excluding lymphoma) that was metastatic or unresectable and for which no standard curative therapy existed. For the renal cell cancer subset, a component of clear This study was conducted in accordance with the Declaration of Helsinki. 155
Drug Administration and Study Design
Sunitinib was supplied in 12.5 mg, 25 mg, and 50 mg capsules. Two treatment schedules were assessed (Figure 1) . On Treatment Schedule A (4/2 schedule), patients initially took one 50 mg capsule of sunitinib daily for 4 consecutive weeks followed by 2 weeks (drug withdrawal) 160 with no sunitinib (6 week cycle). On Treatment Schedule B (2/1 schedule), patients took one 50 mg capsule of sunitinib daily for 2 consecutive weeks followed by 1 week (drug withdrawal) with no sunitinib. This 2/1 schedule was administered every 3 weeks (repeated once) during the 6 week cycle. Pharmacodynamic and pharmacokinetic time points, described in greater detail below and depicted in Figure 1 , included: (1) baseline (before sunitinib treatment), (2) 165 maximum sunitinib exposure (near end of consecutive dosing period), and (3) maximum sunitinib washout (near end of drug withdrawal period).
Research. 
FLT PET/CT Imaging
In order to minimize uncertainties inherent in PET imaging, strict imaging procedures 170 were followed, including: employing optimized and standardized image acquisition and reconstruction protocols, and performing comprehensive image analysis procedures. At the beginning of each imaging session, a CT scan was obtained on a Discovery LS (General Electric, Waukesha, WI) PET/CT scanner. Dynamic PET imaging was performed for the first 30 minutes over the pre-defined region (15 cm field of view) to obtain necessary data for kinetic analysis. 175
After the dynamic scan, a static whole body scan (6 scanning positions ~ 90 cm total length) was initiated at 60 minutes post injection. All scans were acquired in a 2D mode, and reconstructed on a 256x256 reconstruction grid using OSEM iterative reconstruction algorithm with 5 mm post-filtering. The dynamic FLT PET/CT imaging data was used to perform kinetic analysis of the imaging data, thus allowing increased correlation to the biological parameters (cell 180 proliferation index) and extraction of vasculature data (e.g., perfusion/permeability, blood volume). The static whole body FLT PET/CT imaging data was employed to identify primary tumor and metastases. The CT data was analyzed to establish anatomical changes in tumor size.
Each metastasis was identified by an experienced nuclear medicine physician and segmented using a combination of semi-automatic segmentation methods using Amira (Visage Imaging Inc, 185
San Diego, CA) software, with up to five metastases used in image analysis. As the whole body kinetic analysis is impractical, we performed analysis on various standardized uptake value (SUV) measures of FLT uptake. SUV mean , SUV max , SUV peak and SUV total were recorded and analyzed. Multiple SUV measures were investigated to capture intra-lesion response heterogeneity (e.g., most proliferative parts of the tumor (SUV max ) might not respond, even though tumor as whole (SUV mean ) does respond). In order to cross-validate our results, FLT PET SUV measures were compared to measures extracted from the full kinetic analysis. All image analysis was performed at the University of Wisconsin Image Analysis Core (IMAC) facility.
Sunitinib Pharmacokinetic and Plasma VEGF 195
Plasma pharmacokinetic (PK) levels of sunitinib were drawn prior to initiating sunitinib therapy on day 1 and on the days PET scans were performed. In order to monitor changes in serum VEGF levels, samples were collected: on day 1 prior to dosing, weekly during cycle 1, and on day 1 of each subsequent cycle.
Plasma VEGF levels were evaluated using a commercially available 96-well plate Concord, Ontario, Canada). The assay was validated in our laboratory and demonstrated a linear range of 3.12 -100 ng/ml with r 2 = 0.998, with an intraday variability of 3.37% for sunitinib and 6.55% for SU12662. Interday variability was 2.20%/4.03% for the low sunitinib/SU12662 standard of 6.25/3.12 ng/ml; it was 0.45%/0.99% for the 100/50 ng/mL. The LLOQ was 3.12 ng/ml for both sunitinib and SU12662. Recovery based on standard addition was 98.3% for 210 sunitinib and 93.6% for SU12662.
Treatment Response Evaluation
Research. An exploratory, unplanned analysis was added to categorize patients by clinical benefit status (yes/no). Patients who discontinued sunitinib prior to month 6 for any reason (including 220 progression, toxicity, patient/physician discretion, etc.) were categorized as having no clinical benefit (NCB) and those who remained on sunitinib at or after 6 months were categorized as having clinical benefit (CB). Given the heterogeneous patient population (different tumor types, variable prior therapies received, etc.) in this pharmacodynamic trial, this endpoint of clinical benefit was felt to capture additional information not included in the objective response status. 225
The objective response and clinical benefit status were correlated with pharmacodynamic FLT PET imaging data.
Statistical Methods
The study was powered to detect a mean change of 33% in the SUVs parameters at the 230 5% significance level, assuming an anticipated standard deviation ranging from 20 to 30%. A sample size of 10 evaluable patients was planned for each of the two treatment schedules. With a sample size of 10 evaluable patients per treatment schedule, an anticipated mean change of 33% in the SUVs parameters would have been detected with 87% power at the two-sided 5% significance level, assuming a standard deviation of 30%. We anticipated a drop-out rate of up to 235 20% and, hence, accrued a total of 25 patients. FLT PET imaging PD measures, plasma VEGF and PK levels of sunitinib and its metabolite were summarized in terms of medians and ranges for each assessment time point. As the distribution of FLT PET SUV values are known to be left-skewed,(33) non-parametric tests were utilized for performing statistical inference and median profile plots were used to represent 240 the data graphically. Specifically, changes from baseline were evaluated using a nonparametric Wilcoxon signed rank test. Associations between changes in the various PK and imaging PD parameters were analyzed using Spearman's rank correlation (r s ) analysis. Furthermore, in order to adjust the associations between changes in PD parameters for changes in sunitinib concentration, partial Spearman's rank correlation analysis (r ps ) was conducted. The comparison 245 of changes in PD parameters between responders and non-responders was performed using a nonparametric Wilcoxon rank test. All analyses were performed using SAS software version 9.2 (SAS Institute, Cary, NC). All statistical tests were two-sided and P-values less than 0.05 were considered statistically significant. 
250
Results
Patient Characteristics
PET/CT scan were unevaluable for various reasons (FLT production not meeting quality control 260 standard, PET/CT problem, treatment tolerability, etc.), leaving eight evaluable patients each in both treatment schedules. One patient with mRCC (systemic treatment-naïve) on the 2/1 schedule remains on study after 22 cycles of therapy.
Median age was 60 (range: 42 -76), while 75% of subjects were male. As specified by the protocol, nearly half (n = 7) of evaluable patients had mRCC (4/2 schedule: n = 5; 2/1 265 schedule: n = 2). The remainder represented a diverse group of tumor types: esophagus (n = 2), liver (hepatocellular; n = 2), prostate (n = 1), sarcoma (n = 1), small cell lung (n = 1), thymus (n = 1), and uterine carcino-sarcoma (n = 1). Six of seven patients with mRCC had prior nephrectomy. The median number of prior systemic therapy regimens was 1 (range: 0 -4). All subjects were naïve to anti-VEGF therapy, as specified by the protocol. Seven subjects (44%) 270 had been treated with prior chemotherapy, while 3 subjects (19%) had received investigational treatment. One subject with mRCC had undergone treatment with an investigational agent and immunotherapy with interleukin-2, whereas the other 6 patients with mRCC were systemic treatment-naïve.
275
FLT PET/CT Imaging ( Table 1, Figures 2 and 3 ) Figure 2 shows examples of the tumor flare phenomenon on FLT PET/CT in various tumor types. Quantitative assessment of the FLT PET/CT imaging parameters are summarized in Table 1 and Figure 3 . Even though the comprehensive image analysis included many imaging parameters, we report here only the mean standardized uptake value (SUV mean ) and maximum 280 standardized uptake value (SUV max ) because these likely represent distinct parameters of cellular proliferation distribution. The average pre-treatment SUV mean across patient population was 3. The median change from baseline in plasma sunitinib concentrations between baseline 305 and the second PET/CT scan was 63 ng/mL (range 37-184 ng/mL) in the 4/2 cohort and 62 ng/mL (range 32-162 ng/mL) in the 2/1 cohort. The median change from the baseline in plasma sunitinib metabolite concentrations were 20 ng/mL (range 14-39 ng/mL) in the 4/2 cohort and 21 ng/mL (range 4.8-52 ng/mL) in the 2/1 cohort. After sunitinib withdrawal, and at the time of the third PET/CT scan, plasma concentrations declined to near baseline levels. Changes in levels of 310 sunitinib and its metabolite were statistically significant during both the exposure and withdrawal period and in both treatment groups.
Plasma VEGF increased during sunitinib exposure in both treatment groups, as expected.
Likewise, plasma VEGF decreased during sunitinib withdrawal in both treatment groups.
Changes in plasma VEGF were statistically significant during the exposure and withdrawal 315 period and in both treatment groups.
Objective Response Evaluation
There were 16 total patients evaluable for objective response per RECIST 1.0, with an overall objective response rate of 36% (95% CI: 16-61%). The response rate (partial response) 320 for the 4/2 schedule (n = 8) was 38% and the response rate for the 2/1 schedule (n = 8) was 33%.
No complete responses were observed. Of the 16 patients evaluable for FLT PET/CT imaging, only 14 of the patients were evaluable for objective response per RECIST 1.0. Of the two unevaluable patients, one patient with esophageal cancer was taken off study before the planned week 12 disease assessment secondary to a cerebral vascular accident. The second patient 325 (uterine carcino-sarcoma) withdrew consent after 48 days of study participation for personal reasons. 
Correlation Between PK, PD, and Response Parameters
The Spearman's rank correlations (r s ) for the changes from baseline to the end of the 330 treatment and withdrawal period between the various PK and PD parameters (i.e. sunitinib concentration, VEGF, SUV) were calculated and are shown in Table 2 during sunitinib withdrawal. However, the differences between the responder and non-responder groups were not statistically significant by the Wilcoxon rank sum test.
In an exploratory, unplanned analysis, the association between the changes in SUV parameters and the clinical benefit status was evaluated. The clinical benefit rate for both groups combined was 32%: 43% for the 4/2 schedule and 18% for the 2/1 schedule. Figures 4a and 4b  355 shows the median change in SUV max and SUV mean over different scan periods for the clinical benefit (CB) and no clinical benefit (NCB) groups. Subjects with NCB showed a statistically significant increase in SUV mean (+29%; p = 0.012) and SUV max (+45%; p = 0.039) during sunitinib withdrawal. Subjects with CB showed only a trend towards no change in SUV mean (+0.7%; p = 0.238), and a trend towards increase in SUV max (+21%; p = 0.278). 
that despite higher single-agent activity with VEGFR TKI agents (compared to bevacizumab alone), trials reported to date combining VEGFR TKI agents with cytotoxic chemotherapy have 375 not shown the same promise. Phase III trials of carboplatin/paclitaxel with or without sorafenib in both advanced melanoma (34) and NSCLC, (35) 
indicating normalization of blood vessels, in a murine RCC model after 3 days of sunitinib administration, but not after 1 day of sunitinib administration; mice were subsequently treated with weekly gemcitabine. (41) This study suggests that chemotherapy combination with antiangiogenic therapy may be optimized through the use of functional imaging. Understanding how 400 VEGFR TKI therapy may antagonize cytotoxic chemotherapy was another important goal during the analysis of our study, as ongoing trials combining newer VEGFR TKIs with chemotherapy continue.
Here we show that nearly all patients with advanced solid malignancies have some initial reduction in tumor proliferation as measured by FLT PET/CT after 4 weeks of sunitinib 405 treatment. This reduction was more apparent on the 4/2 schedule versus 2/1 schedule, and more significant for the FLT PET SUV max then SUV mean , which is likely due to a greater duration of sunitinib exposure. Nevertheless, in both schedules, during the brief treatment break patients experienced a relative increase in FLT uptake consistent with an increase in tumor proliferation during the treatment withdrawal period. This finding supports our hypothesis and was seen in 410 both the patients with renal cell cancer as well as other solid malignancies. Because of the longer exposure to sunitinib and longer treatment break, we would have predicted that the 4/2 schedule would have a larger "withdrawal flare," but this was not the case. This may simply be due to the low number of patients assessed; however, a complex relationship between the clinical flare, sunitinib PK, and circulating VEGF could also be playing a role. We are addressing this 415 question in currently on-going trials using a VEGFR TKI with a shorter half-life (e.g.
NCT00859118).
During sunitinib exposure, it was observed that most (but not all) patients had some decline in SUV (Figure 3) . Looking at the individual patients (dotted lines), one can begin to One question that might be raised is whether the change in FLT PET uptake we observe is a reflection of tumor proliferation or simply vascular effect (e.g., decreased perfusion in tumor results in decreased tracer delivery resulting in lower FLT uptake). In order to address this question, we performed dynamic FLT PET/CT imaging. Using compartmental modeling 460 (intravascular, extravascular, intracellular), one can calculate K i , which reflects the proliferative rate when corrected for K 1 , which represents the vascular permeability/perfusion (45) . In summary, the FLT PET SUV and FLT PET K i trends were the same, indicating that FLT PET SUV analysis does adequately represent proliferative activity, which is consistent with both clinical and anatomic imaging observations. 465 Table 2 :
Correlations between changes (Δ) in the various pharmacodynamic and pharmacokinetic parameters during sunitinib treatment and withdrawal periods. Associations between changes in the various pharmacokinetic and pharmacodynamic (PD) parameters were 655 analyzed using Spearman's rank correlation (r s ) analysis.
Figures 4a and b:
Change in SUV mean and SUV max (normalized to baseline) by clinical benefit group. Note that the 4/2 and 2/1 schedules are combined so that the abscissa is scaled to sunitinib 660 exposure (and scan time points) instead of time. CB, clinical benefit. NCB, no clinical benefit. ccRCC, clear cell renal cell carcinoma. 
